Trevoux R, van der Velden W H, Popović D
Reproduccion. 1982 Apr-Jun;6(2):101-6.
Eighty-two postmenopausal women with vaginal atrophy and associated symptoms were treated with either Ovestin vaginal cream (54 women) or vaginal suppositories (28 women) containing 0.5 mg of E3/dose, daily for 3 weeks. A maintenance dose of 0.5 mg of E3 twice weekly was applied by all patients for 5 weeks, and by 27 of them for up to 16 weeks. Variables studied were clinical and colposcopic findings, the Maturation Index (MI) and Maturation Value (MV), cervical mucus ferning (F) and spinnbarkeit (S) and endometrial biopsies (obtained pretreatment and after 3 weeks in 15 of the patients). Furthermore, the bio-availability of circulating unconjugated E3 for up to 8 hours following a single dose of Ovestin cream was studied in 10 of the patients. Clinical and colposcopic findings indicated that the treatment had a very favourable effect in all patients. This was reflected in the pronounced change in vaginal smears, indicating a strong oestrogenic effect. There was a slight to moderate effect on cervical mucus. Endometrial biopsies showed that endometrium remained atrophic in all 15 patients in whom biopsies were obtained. A maintenance dose of 0.5 mg of E3 twice weekly appeared to be sufficient to maintain the beneficial effect. Tolerance was good, and patients commented favourably on the treatment.
82名患有阴道萎缩及相关症状的绝经后女性，分别接受了Ovestin阴道乳膏治疗（54名女性）或含0.5mg E3/剂量的阴道栓剂治疗（28名女性），每日一次，持续3周。所有患者均采用0.5mg E3的维持剂量，每周两次，持续5周，其中27名患者持续使用长达16周。研究的变量包括临床和阴道镜检查结果、成熟指数（MI）和成熟值（MV）、宫颈黏液蕨样变（F）和拉丝度（S）以及子宫内膜活检（15名患者在治疗前和3周后进行）。此外，对10名患者研究了单剂量Ovestin乳膏后长达8小时的循环未结合E3的生物利用度。临床和阴道镜检查结果表明，该治疗对所有患者均有非常良好的效果。这反映在阴道涂片的明显变化上，表明有强烈的雌激素作用。对宫颈黏液有轻微至中度影响。子宫内膜活检显示，在所有15名进行活检的患者中，子宫内膜仍呈萎缩状态。每周两次0.5mg E3的维持剂量似乎足以维持有益效果。耐受性良好，患者对治疗评价良好。
